Theravance Biopharma, Inc.
$16.72
▲
1.14%
2026-04-21 09:44:01
www.theravance.com
NGM: TBPH
Explore Theravance Biopharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$877.44 M
Current Price
$16.72
52W High / Low
$21.03 / $8.33
Stock P/E
8.29
Book Value
$5.81
Dividend Yield
—
ROCE
-0.81%
ROE
44.84%
Face Value
—
EPS
$2.06
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
90
Beta
0.17
Debt / Equity
14.39
Current Ratio
10.93
Quick Ratio
10.93
Forward P/E
12.07
Price / Sales
7.83
Enterprise Value
$569.26 M
EV / EBITDA
-288.08
EV / Revenue
5.3
Rating
Buy
Target Price
$17.2
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Scholar Rock Holding Corporation | $47.8 | — | $5.49 B | — | -110.26% | -1.23% | $51.62 / $27.07 | $2.26 |
| 2. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 3. | XOMA Royalty Corporation | $40 | 14.61 | $463.38 M | 1.18% | 4.79% | 34.12% | $40.74 / $20.59 | $7.07 |
| 4. | Keros Therapeutics, Inc. | $11.66 | 2.64 | $230.1 M | — | 21.27% | 19.9% | $22.55 / $10.41 | $15.51 |
| 5. | ARS Pharmaceuticals, Inc. | $8.18 | — | $812.25 M | — | -62.2% | -92.33% | $18.9 / $6.66 | $1.15 |
| 6. | Connect Biopharma Holdings Limited | $2.68 | — | $158.82 M | — | -24.19% | -82.72% | $3.82 / $0.65 | $0.74 |
| 7. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 45.89 M | 19.99 M | 26.2 M | 15.39 M | 18.75 M | — |
| Operating Profit | 20.01 M | -6.46 M | -2.73 M | -14.43 M | -9.2 M | — |
| Net Profit | 61.02 M | 3.62 M | 54.84 M | -13.58 M | -15.53 M | — |
| EPS in Rs | 1.19 | 0.07 | 1.06 | -0.26 | -0.3 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 107.46 M | 64.38 M | 57.42 M | 51.35 M |
| Operating Profit | -3.6 M | -42.44 M | -53.29 M | -79.12 M |
| Net Profit | 105.89 M | -56.42 M | -55.19 M | 872.13 M |
| EPS in Rs | 2.06 | -1.1 | -1.07 | 16.94 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 485.57 M | 354.16 M | 382 M | 607.4 M |
| Total Liabilities | 188.85 M | 178.62 M | 169 M | 165.6 M |
| Equity | 296.72 M | 175.54 M | 213 M | 441.8 M |
| Current Assets | 418.46 M | 161.07 M | 133.54 M | 353.46 M |
| Current Liabilities | 38.3 M | 32.09 M | 24.77 M | 28.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 238.54 M | -11.54 M | -27 M | -186.99 M |
| Investing CF | -105.28 M | 12.28 M | -32.7 M | 1.15 B |
| Financing CF | -3.25 M | -2.5 M | -198.93 M | -758.81 M |
| Free CF | 238.5 M | -11.87 M | -29.48 M | -187.56 M |
| Capex | -0.04 M | -0.33 M | -2.49 M | -0.57 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 12.12% | 11.84% | — | — |
| Earnings Growth % | -2.22% | -106.33% | — | — |
| Profit Margin % | -87.63% | -96.11% | 1698.54% | — |
| Operating Margin % | -65.91% | -92.8% | -154.09% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -59.73% | -74.29% | -154.68% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.